Treating Meningococcal Disease: Ceftriaxone, Dexamethasone, and ICU Care

  1. Time to First Antibiotic
  2. Ceftriaxone — the Antibiotic of Choice
  3. Pre-Hospital Benzylpenicillin
  4. Dexamethasone — Reducing Brain Damage
  5. Alternatives When Ceftriaxone Unavailable
  6. Duration and Monitoring
  7. Managing Raised Intracranial Pressure
  8. Septic Shock Management in the ICU
  9. Limb Ischemia and Amputation Decisions
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Time to First Antibiotic — the Most Important Number

In meningococcal disease, speed matters more than almost anything else. Every hour of delay in administering antibiotics is associated with measurably worse outcomes. In the most rapidly progressive meningococcemia cases, delay of even 30 to 60 minutes can be the difference between survival and death.

The bacteria are multiplying exponentially, releasing endotoxin with each cell division. The inflammatory cascade triggered by this endotoxin is what kills — not the bacteria themselves. Getting antibiotics into the bloodstream as fast as possible blunts this chain reaction before it becomes irreversible.

If the patient is in a setting without IV access — for example, a GP's office or a school nurse's room — intramuscular benzylpenicillin should be given before ambulance transfer. The time it takes to establish IV access in a clinic is rarely worth the benefit compared to giving an IM injection immediately and calling 999 or 911.

Guidelines from the UK recommend that suspected cases receive antibiotics within 30 minutes of hospital arrival. Anything beyond one hour from door to antibiotic is associated with significantly higher mortality. If you suspect meningococcal disease, do not wait for test results — treat first.

Back to Table of Contents

Ceftriaxone — the Antibiotic of Choice

Ceftriaxone is the preferred antibiotic for treating bacterial meningitis and meningococcemia in most high-income countries. It is a third-generation cephalosporin with excellent CSF penetration — a critical property because the blood-brain barrier limits many antibiotics from reaching therapeutic concentrations in the cerebrospinal fluid.

Standard dosing is:

Ceftriaxone covers N. meningitidis reliably, but it also covers Listeria monocytogenes and Streptococcus pneumoniae — the other common causes of bacterial meningitis. This broad spectrum coverage is important because in the first hours of treatment, the exact pathogen is often unknown. You treat empirically for all likely pathogens.

One practical advantage of ceftriaxone over penicillin is that it reliably clears nasopharyngeal carriage of meningococci. Penicillin treats systemic infection but does not eradicate throat carriage — so a patient treated with penicillin may still need a separate decolonization course before discharge to prevent them from spreading bacteria to household contacts.

Back to Table of Contents

Pre-Hospital Benzylpenicillin — the "Give Before You Go" Drug

Benzylpenicillin (penicillin G) given before hospital transfer has been a cornerstone of UK meningococcal disease management for decades. The rationale is simple: transfer from a GP surgery or community setting to a hospital can take 30 to 60 minutes. If the patient has meningococcemia, every minute of delay costs lives. An IM injection of benzylpenicillin takes 60 seconds and begins working within minutes.

Recommended doses for pre-hospital use:

Fear of penicillin allergy sometimes prevents first-responders from giving this drug. In life-threatening meningococcal disease, this is generally misguided. Documented severe penicillin allergy is rare (true anaphylaxis occurs in roughly 1 in 50,000 doses). In a patient who will die without antibiotics, the risk-benefit calculation strongly favors giving benzylpenicillin. The exception is a well-documented history of anaphylaxis to penicillin, in which case ceftriaxone IM 2g (adults) may be used by pre-hospital providers who carry it.

The UK Meningitis Research Foundation and NICE guidelines both support pre-hospital penicillin administration. The historical controversy about whether it helped or hindered (by potentially obscuring CSF culture results) has been largely resolved — getting antibiotics in early saves lives, even if it makes microbiological diagnosis slightly harder.

Back to Table of Contents

Dexamethasone — Reducing Brain Damage and Hearing Loss

Dexamethasone is a corticosteroid given alongside antibiotics to reduce the brain's inflammatory response. The standard protocol is 0.15mg/kg IV every 6 hours for 4 days. The most critical rule about dexamethasone is timing: it must be given with the first antibiotic dose, or ideally 15–30 minutes before. Giving it after antibiotics have already been running for several hours loses most of the benefit.

Here is why timing matters so much: when antibiotics kill bacteria, the bacterial cell walls break apart and release large amounts of endotoxin suddenly. This triggers a massive inflammatory response — cytokines flood the CSF, white cells rush in, and the resulting inflammation damages brain tissue and the acoustic nerve. Dexamethasone, given before this "endotoxin dump," blocks the inflammatory mediators before they can cause damage.

The evidence base is strongest for reducing hearing loss in Streptococcus pneumoniae meningitis. In the landmark European trial by de Gans and van de Beek (2002), dexamethasone reduced unfavorable outcomes by almost half and reduced mortality from 15% to 7% in adults with bacterial meningitis. For meningococcal meningitis specifically, the benefit on hearing and neurological outcome is less certain but is considered standard of care in most guidelines because the treatment is low-cost and the potential downside is minimal at 4 days of dosing.

Dexamethasone should not be given if the patient is already on immunosuppressive therapy for another condition, if there is a specific contraindication to steroids, or if the diagnosis is not bacterial meningitis.

Back to Table of Contents

Alternatives When Ceftriaxone Unavailable

In resource-limited settings, or in patients with specific allergies, alternatives to ceftriaxone exist:

In all cases, local antimicrobial resistance patterns should guide definitive therapy once susceptibility results are available from blood culture or CSF culture.

Back to Table of Contents

Duration and Monitoring

The standard course of IV antibiotics for meningococcal meningitis is 7 days. Some guidelines recommend 10 days, particularly if the patient is slow to improve or if the infecting organism was not definitively confirmed as N. meningitidis. An oral switch to antibiotics after IV therapy is generally not done for bacterial meningitis — the full course is given IV.

Monitoring during treatment includes:

Before discharge, the medical team should ensure that close contacts have received chemoprophylaxis and that the local public health authority has been notified to coordinate contact tracing.

Back to Table of Contents

Managing Raised Intracranial Pressure

Raised intracranial pressure (ICP) is a life-threatening complication of meningitis. When the brain swells inside a rigid skull, pressure builds up and can reduce blood flow to the brain. At its extreme, this causes coning — herniation of the brainstem through the foramen magnum — which is rapidly fatal.

Key management strategies for raised ICP in meningitis include:

Back to Table of Contents

Septic Shock Management in the ICU

Meningococcemia — meningococcal bacteremia without meningitis, or combined with meningitis — can cause one of the most rapid and devastating forms of septic shock known to medicine. The bacteria release enormous quantities of endotoxin which triggers systemic inflammatory response syndrome, capillary leak, and distributive shock. Patients can go from mildly unwell to cardiovascular collapse within hours.

ICU management follows the general principles of septic shock but with some meningococcal-specific considerations:

Back to Table of Contents

Limb Ischemia and Amputation Decisions

One of the most heartbreaking complications of meningococcal septicemia is limb loss. The DIC triggered by the bacteria causes microthrombi throughout the small vessels, cutting off blood supply to fingers, toes, hands, and feet. Combined with the shock state and widespread vasospasm, this can progress to digital gangrene or full limb ischemia within hours.

During the acute phase, a number of interventions are tried to preserve limb perfusion:

Amputation decisions are never made during the acute phase. Once the patient has survived the infection and is medically stable — typically weeks later — the line of demarcation between viable and non-viable tissue becomes clear. Surgeons wait until this line is established before deciding the level of amputation. Early amputation during active sepsis risks removing more tissue than necessary and increases operative risk in an already unstable patient.

Young survivors of meningococcal disease who lose limbs can achieve remarkable functional rehabilitation with modern prosthetics. The meningococcal community has a strong advocate and peer-support network — connecting families with survivor groups early is as important as any medical intervention.

Back to Table of Contents

Key Research Papers

  1. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549–1556. PMID 14534308
  2. Proulx N, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM. 2005;98(4):291–298. PMID 15760921
  3. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467–492. PMID 20610819
  4. Tunkel AR, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–1284. PMID 15494903
  5. Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child. 2003;88(7):608–614. PMID 12818909
  6. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196–2210. PMID 17604802
  7. Rosenstein NE, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388. PMID 11333996
  8. Peltola H, Roine I. Influence of intensity of antimicrobial therapy on the course of bacterial meningitis. Curr Opin Neurol. 2009;22(3):346–352. PMID 19421063
  9. Sprung CL, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–124. PMID 18184957
  10. Edmond K, et al. Global and regional risk of disabling sequelae from bacterial meningitis. Lancet Infect Dis. 2010;10(5):317–328. PMID 20417414

Back to Table of Contents

Connections

Back to Table of Contents